Trials / Completed
CompletedNCT01250795
Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In Adults
A Phase 1a/b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Reactogenicity, and Immunogenicity of FhCMB HAI-05, a Recombinant Hemagglutinin (rHA) Vaccine Derived From Influenza A/Indonesia/05/2005 (H5N1), in Healthy Adults 18 to 49 Years
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Fraunhofer, Center for Molecular Biotechnology · Industry
- Sex
- All
- Age
- 18 Years – 49 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the safety, immunogenicity,and tolerability of a H5N1 Vaccine in healthy adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | HAI-05 Influenza Vaccine | injection, vaccine, twice every 3 weeks |
| OTHER | Saline |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2011-07-01
- Completion
- 2011-07-01
- First posted
- 2010-12-01
- Last updated
- 2016-05-12
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01250795. Inclusion in this directory is not an endorsement.